Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD
NCT03622541
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
46
Enrollment
OTHER
Sponsor class
Conditions
FLT3-ITD Mutation
AML
Interventions
DRUG:
Sorafenib 200mg
Sponsor
The University of Hong Kong